English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Drug repurposing for aging research using model organisms

MPS-Authors

Ziehm,  M.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Kaur,  S.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Ivanov,  D. K.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Ballester,  P. J.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Marcus,  D.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Partridge,  L.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Thornton,  J. M.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Ziehm, M., Kaur, S., Ivanov, D. K., Ballester, P. J., Marcus, D., Partridge, L., et al. (2017). Drug repurposing for aging research using model organisms. Aging Cell. doi:10.1111/acel.12626.


Cite as: http://hdl.handle.net/21.11116/0000-0001-5942-1
Abstract
Many increasingly prevalent diseases share a common risk factor: age. However, little is known about pharmaceutical interventions against aging, despite many genes and pathways shown to be important in the aging process and numerous studies demonstrating that genetic interventions can lead to a healthier aging phenotype. An important challenge is to assess the potential to repurpose existing drugs for initial testing on model organisms, where such experiments are possible. To this end, we present a new approach to rank drug-like compounds with known mammalian targets according to their likelihood to modulate aging in the invertebrates Caenorhabditis elegans and Drosophila. Our approach combines information on genetic effects on aging, orthology relationships and sequence conservation, 3D protein structures, drug binding and bioavailability. Overall, we rank 743 different drug-like compounds for their likelihood to modulate aging. We provide various lines of evidence for the successful enrichment of our ranking for compounds modulating aging, despite sparse public data suitable for validation. The top ranked compounds are thus prime candidates for in vivo testing of their effects on lifespan in C. elegans or Drosophila. As such, these compounds are promising as research tools and ultimately a step towards identifying drugs for a healthier human aging.